Biomarker Testing in Advanced NSCLC: A Community Oncology Perspective
Martin Dietrich, MD, PhD
Medical Oncologist,
Florida Hospital Cancer Institute,
Orlando, Florida
Dr. Dietrich reviews FDA-approved and emerging biomarkers in NSCLC, and discusses the importance of a multidisciplinary approach and proper biopsy technique in facilitating a successful and timely molecular characterization of NSCLC
CASE STUDY ON BIOMARKER TESTING IN ADVANCED NSCLC
Case Study
Patient Case: Biomarker Testing in Advanced NSCLC
Chung-Che (Jeff) Chang, MD, PhD
A Case-Based Pathology Perspective on Biomarker Testing in NSCLC
Gaetane C. Michaud, MD
A Case-Based Pulmonology Perspective on Biomarker Testing in NSCLC
Mark A. Socinski, MD
A Case-Based Oncology Perspective on Biomarker Testing in NSCLC
IN ADVANCED NSCLC
Chung-Chee (Jeff) Chang, MD, PhD
A Pathology Perspective on Biomarker Testing in NSCLC
Martin Dietrich, MD, PhD
A Community Oncology Perspective on Biomarker Testing in NSCLC
Gaetane C. Michaud, MD
A Pulmonology Perspective on Biomarker Testing in NSCLC
Mark A. Socinski, MD
An Oncology Perspective on Biomarker Testing in NSCLC
